Lyell Immunopharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Lyell Immunopharma Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LYEL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001806952
- EIN
- 83-3006753
Board of directors
-
Cathy Friedman · DirectorSince 2023
-
Elizabeth G. Nabel · DirectorSince 2023
-
Hans Edgar Bishop · DirectorSince 2023
-
Lynn Seely · Director · President and CEOSince 2023
-
Mark Bachleda · DirectorSince 2025
-
Otis W. Brawley · DirectorSince 2023
-
Richard Klausner · DirectorSince 2023
- Since 2023
-
Sumant Ramachandra · DirectorSince 2024
-
William Jl Rieflin · DirectorSince 2023
Chief executives
Lynn Seely
· President and CEO
Dates unknown
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.7%
-
99.2%
-
99.3%
Board connections
7 of this board's directors also sit on 12 other boards.
- via Hans Edgar Bishop and Otis W. Brawley
- via Hans Edgar Bishop and Robert Nelsen
- via Lynn Seely
- via Otis W. Brawley
- via Robert Nelsen
- via Elizabeth G. Nabel
- via Elizabeth G. Nabel
- via Otis W. Brawley
- via Richard Klausner
- via Robert Nelsen
- via Cathy Friedman
- via Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $24,999,970
- 2 purchases by 2 insiders
- Sold, last 12 months
- $604,586
- 28 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Shook David Officer (Chief Medical Officer) | Open-market sale | −500 | $12.70 | $6,350 |
| Aug 21, 2026 | Hill Stephen J. Officer (Chief Operating Officer) | Open-market sale | −989 | $15.54 | $15,369 |
| Aug 21, 2026 | Lee Gary K. Officer (Chief Scientific Officer) | Open-market sale | −1,457 | $15.54 | $22,642 |
| Aug 21, 2026 | Lynn Seely Director, Officer (President and CEO) | Open-market sale | −9,589 | $15.54 | $149,013 |
| Aug 10, 2026 | Bulis Veronica Sanchez Officer (VP, Corporate Controller) | Open-market sale | −621 | $14.34 | $8,905 |
| Aug 10, 2026 | Hill Stephen J. Officer (Chief Operating Officer) | Open-market sale | −89 | $14.34 | $1,276 |
| Aug 10, 2026 | Lee Gary K. Officer (Chief Scientific Officer) | Open-market sale | −131 | $14.34 | $1,879 |
| Aug 10, 2026 | Lynn Seely Director, Officer (President and CEO) | Open-market sale | −390 | $14.34 | $5,593 |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | −38,500 | — | — |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | −44,000 | — | — |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Open-market sale | −10 | $13.70 | $137 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Open-market sale | −10 | $13.73 | $137 |
| Jun 29, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | −76,000 | — | — |
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other | −66,500 | — | — |
| Jun 10, 2026 | Shook David Officer (Chief Medical Officer) | Open-market sale | −1,977 | $12.64 | $24,989 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.